Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study

Eur J Cancer. 2006 Nov;42(17):3004-14. doi: 10.1016/j.ejca.2006.02.026. Epub 2006 Sep 7.


Aim: Improvement of EFS of children older than 3 years with high risk medulloblastoma.

Methods: Between 1993 and 1999, 115 patients (3-18 years, mean 8 years) with high risk medulloblastoma were included. After surgery treatment consisted of chemotherapy ('8in1' and etoposide/carboplatin) before and after craniospinal radiotherapy.

Results: Patients were staged using Chang-criteria (PF residue only, M1 and M2/M3) by local investigator as well as by central review panel (82.4% concordance). Chemotherapy was well tolerated without major delays in radiotherapy. With a mean follow up of 81 months (9-119), 5-year EFS was 49.8% and OS 60.1%. In detail according to subgroups EFS was 68.8% for PF residue only, 58.8% for M1 disease and 43.1% for M2/M3.

Conclusion: M1 patients are legitimate high risk patients. Survival rates are still very low for high risk medulloblastoma patients and future trials should therefore focus on more intensive (chemotherapy/radiotherapy) treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carboplatin / administration & dosage
  • Cerebellar Neoplasms* / drug therapy
  • Cerebellar Neoplasms* / radiotherapy
  • Cerebellar Neoplasms* / surgery
  • Child
  • Child, Preschool
  • Combined Modality Therapy / methods
  • Disease-Free Survival
  • Etoposide / administration & dosage
  • Humans
  • Medulloblastoma* / drug therapy
  • Medulloblastoma* / radiotherapy
  • Medulloblastoma* / surgery
  • Postoperative Care
  • Prospective Studies
  • Risk Factors
  • Treatment Outcome


  • Etoposide
  • Carboplatin